TTrialPathMatch Me to Trials
← Back to trials
RecruitingChronic Kidney DiseasesObesity

Sit Less, Interact and Move More (SLIMM) 2 Study

Eligible age

20+ yrs

Accepts

All genders

Locations

2 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

* Prolonged sitting (sedentary behavior) is a risk factor for decreased kidney function, obesity, diabetes and mortality. Prolonged sitting is associated with decreased kidney function and increased risk of diabetes, heart disease and death. * In a previous pilot study funded by NIH, it was shown that a Sit Less, Interact and Move More (SLIMM) intervention targeting sedentary behavior in people with kidney disease was able to decrease prolonged sitting but that effect was not sustained. * Therefore, the researchers are currently conducting a follow-up study named Sit Less, Interact and Move More (SLIMM) 2. * This NIH funded study is conducted at the University of Utah and Stanford University. * The purpose of this study is to see if guided resistance training (to improve muscle strength) and semaglutide (FDA approved diabetes and weight loss medication that might also improve physical function) can boost adherence to the SLIMM Intervention and reduce sedentary behavior.

Sponsor: Srinvasan Beddhu

You may qualify if…

  • Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Glomerular Filtration Rate (eGFR) 20 to \<60 mL/min/1.73m\^2
  • Able to perform resistance training
  • Access to compatible "smartphone" or device (i.e., Android, Kindle or Apple with internet connectivity or mobile network), desktop or laptop

You may not qualify if…

  • Type 1 Diabetes
  • History of gastroparesis or paralytic ileus
  • At baseline, if sedentary time is 25 min/hr or less, measured by accelerometer
  • Potential contraindications to semaglutide such as a history of pancreatitis, and a family or personal history of multiple endocrine neoplasia type 2 or familial medullary thyroid carcinoma.
  • Previous bariatric surgery
  • Medical condition likely to limit survival to less than 1 year
  • Anticipated start of dialysis or kidney transplantation within 6 months
  • Any factors judged by the investigator or study team to likely limit adherence to interventions

Where it's recruiting

California

Stanford

Utah

Salt Lake City

Source: ClinicalTrials.gov · NCT05173714 · last updated 2026-07-27

Sit Less, Interact and Move More (SLIMM) 2 Study · TrialPath